Vendor Considerations in an AI-Driven Pharmaceutical Ecosystem



Key Takeaways
  • FDA intends to regulate AI in drug development with its existing tools, focusing on nonclinical, clinical, post-marketing, and manufacturing phases — not on drug discovery or efficiencies that don’t affect patient safety or data reliability.
  • FDA’s draft guidance sets out a 7-step, risk-based AI credibility framework, plus a credibility assessment plan and report, a lifecycle maintenance plan, and early FDA engagement.
  • Companies must also comply with state AI laws (Colorado, California, and Utah) and consumer-protection rules that impose obligations on high-risk AI uses.
  • Vendor contracts should require regulatory compliance, full data and model transparency, active risk and lifecycle management, ethical AI practices, and immediate issue reporting.
  • Ownership and control of data — before, during, and after an FDA submission — is the single most critical consideration in any life sciences AI transaction.

AI vendor agreements in pharma: Hogan Lovells logo over glass medicine vials on a production line.

Submitted by Jason Conaty and Ashley Grey | Hogan Lovells.
Originally published in Life Sciences Insights Magazine, August 2025


The pharmaceutical industry is undergoing a profound transformation driven by advances in AI that are reshaping every stage of the product lifecycle — from drug discovery and clinical trials to manufacturing, marketing, and real-world evidence (RWE) generation. AI’s use in the development process, including in the rapid development of COVID-19 vaccines, has shown that AI-driven innovation can drastically shorten the drug development timeline. AI’s success in accelerating the development timelines of FDA-approved drugs has ushered in an era marked by the growing embeddedness of AI within core functions at life sciences companies, and increasing prominence and importance of AI governance. As AI becomes more broadly implemented for regulated products and functions, aligning AI governance with traditional regulatory frameworks is essential. Given the robust regulations pharmaceutical and biotechnology companies face, evolving state laws, and regulatory uncertainty caused by the absence of comprehensive federal AI legislation, companies will need to exercise critical judgment in applying best practices to AI hygiene. FDA’s recent draft guidance on AI in regulatory decision-making introduces a comprehensive risk-based AI credibility framework for drugs and biologics and may prompt biopharmaceutical companies to flow down key responsibilities to AI technology vendors to help maintain regulatory compliance.


The Regulatory Framework for AI Used in Drug Development

FDA’s recent draft guidance on AI in regulatory decision-making makes clear that the agency intends to regulate AI used in drug development using its traditional regulatory tools. Limiting its regulatory authority to nonclinical, clinical, post-marketing, and manufacturing phases of the drug and biologic lifecycle, FDA does not intend to regulate AI use for drug discovery and operational efficiencies that do not impact patient safety, drug quality, or the reliability of results from a nonclinical or clinical study.

Key regulatory expectations set out in the draft guidance include:

A 7-step risk-based framework, which FDA expects sponsors to use to assess AI model credibility.

Credibility assessment plan, which would be submitted to FDA and comprehensively outline the model’s design, data strategy, training methodologies, performance metrics and evaluation methodologies.

Credibility assessment report, compiled from the execution of the credibility assessment plan. The report should include a comprehensive description of the outcomes of the plan, confirm the AI model’s credibility for its intended context of use (COU), outline any deviations from the plan, and be submitted to FDA early in the process, either within a regulatory submission or upon request during an inspection.

Lifecycle maintenance plan to ensure continuous monitoring and maintenance of AI model performance throughout its lifecycle, considering ongoing updates and new data.

Early engagement with FDA to navigate evolving regulatory expectations.

In addition, life sciences companies will need to comply with state laws regulating AI (such as Colorado, California, and Utah) and consumer protection, which often impose obligations, like notification, on high-risk uses of AI (e.g., AI-enabled digital health technologies (DHTs) which are used by patients in clinical trials or AI-generated fake testimonials in advertising).

To help life sciences companies comply with both FDA guidance and emerging state-level AI regulations, the following section outlines key considerations when entering into vendor agreements with AI developers.


Key Considerations for AI Tools and Vendor Agreements

Pharmaceutical and biotechnology companies must first assess whether an AI tool meets the FDA’s definition of AI. This distinction is critical because regulatory obligations hinge on whether the tool is considered AI based on FDA or the relevant state regulator’s definition of AI. For purposes of FDA regulation, AI is any machine-based system that, given human-defined objectives, generates predictions, recommendations, or decisions affecting real or virtual environments. Early FDA engagement is essential when using generative AI in these contexts.

Next, companies must clearly define the AI tool’s intended use, including:

How it will be applied (e.g., clinical trial design, manufacturing control, pharmacovigilance, marketing analytics).

Whether the use falls under FDA or state regulatory scope.

Potential for expansion into regulated areas triggering additional obligations.

It is critical to confirm the AI tool is fit for purpose within its defined context of use and meets FDA expectations for AI credibility set out in its guidance.

When entering into agreements with AI vendors, pharmaceutical companies must ensure contracts reflect regulatory requirements and enable effective risk management under FDA’s evolving AI framework.

Pharmaceutical companies should ensure agreements require vendors to:

Comply with all applicable regulations, including FDA Quality System Regulations, Part 11 electronic records requirements, and relevant state laws governing AI use and data privacy. This includes obligations around data integrity, cybersecurity, and timely reporting of cybersecurity attacks, access to personally identifiable information (especially health information), or system malfunctions.

Provide full transparency, access to data and model information, and clear delineation of data ownership and confidentiality, including raw data, training sets, audit trails, and performance metrics, enabling the sponsor to conduct thorough audits, and to support regulatory submissions.

Participate actively in AI risk assessments and lifecycle management by supporting continuous monitoring, model retraining, and prompt notification of any changes that could impact product safety, efficacy, or regulatory compliance.

Adhere to ethical AI practices and align with corporate AI governance or technology policies such as transparency, data privacy, and responsible AI use.

Maintain clear communication channels to report any issues affecting system performance, compliance, or data integrity immediately, ensuring that the sponsor can meet its regulatory reporting and oversight obligations.

Embedding these responsibilities into vendor contracts helps pharmaceutical companies manage risk, ensure compliance with evolving FDA guidance, and maintain control over critical AI tools across drug development, manufacturing, and application submission. Of course, companies should also incorporate consumer protection, environmental, social, and governance (ESG) principles; ethics; and sustainability considerations into AI vendor agreements to support responsible innovation, long-term corporate accountability, and existing company policies and goals. But most critically, data is the beating heart not only of AI, but also successful drug and biologic development. Ownership and control of data, before, during, and after an application is submitted to FDA is critical to protecting innovation and return on investment. It should be uppermost in mind in navigating life sciences AI transactions.


AI regulation remains a rapidly evolving landscape. At Hogan Lovells, we advised both emerging companies and global multinationals across the life sciences sector, helping them navigate regulatory uncertainty and seize opportunities in the next era of health care transformation. Our California-based team is particularly well positioned at the intersection of technology, life sciences, and policy, allowing us to support clients at the forefront of innovation and compliance.



Get the latest thought leadership from California’s life sciences sector in the quarterly Life Sciences Insights magazine. Share your own news and insights with CLS Member Voice.



FAQ: AI Vendor Considerations in the Pharmaceutical Industry

FDA’s draft guidance says the agency will regulate AI in drug development using its traditional regulatory tools, focused on the nonclinical, clinical, post-marketing, and manufacturing phases of the drug and biologic lifecycle. It does not intend to regulate AI used purely for drug discovery or operational efficiencies that do not affect patient safety, drug quality, or the reliability of study results.

It is a 7-step, risk-based approach FDA expects sponsors to use to assess an AI model’s credibility for its intended context of use. The framework is supported by a credibility assessment plan, a credibility assessment report, a lifecycle maintenance plan for ongoing monitoring, and early engagement with FDA.

Contracts should require vendors to comply with all applicable FDA and state regulations, provide full transparency and access to data and model information, participate in AI risk assessments and lifecycle management, adhere to ethical AI practices, and report issues immediately. Clear delineation of data ownership, audit trails, and cybersecurity obligations is essential.

Yes. In the absence of comprehensive federal AI legislation, state laws — such as those in Colorado, California, and Utah — and consumer-protection rules impose additional obligations, often including notification requirements for high-risk AI uses like AI-enabled digital health technologies or AI-generated advertising testimonials.

Data is the foundation of both AI performance and successful drug and biologic development. Ownership and control of data — before, during, and after an FDA submission — is critical to protecting innovation and return on investment, which is why it should be the central consideration in any life sciences AI transaction.